{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:26:57Z","timestamp":1787164017237,"version":"build-2736575974"},"reference-count":354,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T00:00:00Z","timestamp":1649980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>A key issue with modern cancer treatments is the emergence of resistance to conventional chemotherapy and molecularly targeted medicines. Cancer nanotherapeutics were created in order to overcome the inherent limitations of traditional chemotherapeutics. Over the last few decades, cancer nanotherapeutics provided unparalleled opportunities to understand and overcome drug resistance through clinical assessment of rationally designed nanoparticulate delivery systems. In this context, various design strategies such as passive targeting, active targeting, nano-drug, and multimodal nano-drug combination therapy provided effective cancer treatment. Even though cancer nanotherapy has made great technological progress, tumor biology complexity and heterogeneity and a lack of comprehensive knowledge of nano-bio interactions remain important roadblocks to future clinical translation and commercialization. The current developments and advancements in cancer nanotherapeutics employing a wide variety of nanomaterial-based platforms to overcome cancer treatment resistance are discussed in this article. There is also a review of various nanotherapeutics-based approaches to cancer therapy, including targeting strategies for the tumor microenvironment and its components, advanced delivery systems for specific targeting of cancer stem cells (CSC), as well as exosomes for delivery strategies, and an update on clinical trials. Finally, challenges and the future perspective of the cancer nanotherapeutics to reverse cancer drug resistance are discussed.<\/jats:p>","DOI":"10.3390\/pharmaceutics14040866","type":"journal-article","created":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T02:39:31Z","timestamp":1650335971000},"page":"866","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Emerging Nanotherapeutic Approaches to Overcome Drug Resistance in Cancers with Update on Clinical Trials"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8125-7972","authenticated-orcid":false,"given":"Syed Nasir Abbas","family":"Bukhari","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry, College of Pharmacy, Jouf University, Sakaka 72388, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA A Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA A Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.4103\/jcrt.JCRT_976_17","article-title":"Therapeutic approaches targeting cancer stem cells","volume":"14","author":"Pan","year":"2018","journal-title":"J. Cancer Res. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1200\/JCO.2018.78.8240","article-title":"Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Targeted Therapy","volume":"36","author":"Copur","year":"2018","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1158\/1078-0432.CCR-14-1429","article-title":"Translational implications of tumor heterogeneity","volume":"21","author":"Quezada","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41368-020-00087-0","article-title":"Radiotherapy targeting cancer stem cells \u201cawakens\u201d them to induce tumour relapse and metastasis in oral cancer","volume":"12","author":"Liu","year":"2020","journal-title":"Int. J. Oral Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","article-title":"A view on drug resistance in cancer","volume":"575","author":"Vasan","year":"2019","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"100769","DOI":"10.1016\/j.drup.2021.100769","article-title":"The role of endolysosomal trafficking in anticancer drug resistance","volume":"57","author":"Hussein","year":"2021","journal-title":"Drug Resist. Updates"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-021-01746-w","article-title":"Deciphering molecular mechanisms underlying chemoresistance in relapsed AML patients: Towards precision medicine overcoming drug resistance","volume":"21","author":"Levin","year":"2021","journal-title":"Cancer Cell Int."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"100742","DOI":"10.1016\/j.drup.2020.100742","article-title":"Taxanes in cancer treatment: Activity, chemoresistance and its overcoming","volume":"54","author":"Mosca","year":"2021","journal-title":"Drug Resist. Updates"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"100743","DOI":"10.1016\/j.drup.2021.100743","article-title":"Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance","volume":"54","author":"Wang","year":"2021","journal-title":"Drug Resist. Updates"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"100777","DOI":"10.1016\/j.drup.2021.100777","article-title":"Novel nanomedicines to overcome cancer multidrug resistance","volume":"58","author":"Su","year":"2021","journal-title":"Drug Resist. Updates"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature10738","article-title":"Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing","volume":"481","author":"Ding","year":"2012","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Garcia-Mayea, Y., Mir, C., Masson, F., Paciucci, R., and LLeonart, M. (2020). Insights into new mechanisms and models of cancer stem cell multidrug resistance. Seminars in Cancer Biology, Academic Press.","DOI":"10.1016\/j.semcancer.2019.07.022"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.7150\/thno.48662","article-title":"Nanomedicine of tyrosine kinase inhibitors","volume":"11","author":"Smidova","year":"2021","journal-title":"Theranostics"},{"key":"ref_16","first-page":"1","article-title":"Targeting cancer stem cells for reversing therapy resistance: Mechanism, signaling, and prospective agents","volume":"6","author":"Zhou","year":"2021","journal-title":"J Signal Transduct. Target. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"102681","DOI":"10.1016\/j.jddst.2021.102681","article-title":"Insight of nanomedicine strategies for a targeted delivery of nanotherapeutic cues to cope with the resistant types of cancer stem cells","volume":"64","author":"Mao","year":"2021","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ejphar.2018.07.034","article-title":"Molecular targeted therapy: Treating cancer with specificity","volume":"834","author":"Lee","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4103\/apjon.apjon_79_17","article-title":"Targeted therapy: Attacking cancer with molecular and immunological targeted agents","volume":"5","author":"Wilkes","year":"2018","journal-title":"Asia-Pac. J. Oncol. Nurs."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.canlet.2018.01.074","article-title":"Andrographolide, a diterpene lactone from Andrographis paniculata and its therapeutic promises in cancer","volume":"420","author":"Islam","year":"2018","journal-title":"Cancer Lett."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.bbamcr.2016.05.006","article-title":"The glucagon-like peptide-1 analogue exendin-4 reverses impaired intracellular Ca2+ signalling in steatotic hepatocytes","volume":"1863","author":"Ali","year":"2016","journal-title":"Biochim. Et Biophys. Acta -Mol. Cell Res."},{"key":"ref_22","first-page":"25","article-title":"Non-small-cell lung cancer: Molecular targeted therapy and personalized medicine\u2013drug resistance, mechanisms, and strategies","volume":"6","author":"Sechler","year":"2013","journal-title":"Pharm. Pers. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3389\/fonc.2014.00190","article-title":"Drug resistance to molecular targeted therapy and its consequences for treatment decisions in non-small-cell lung cancer","volume":"4","author":"Spaans","year":"2014","journal-title":"Front. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.phrs.2017.05.010","article-title":"Exploring the potential of nanotherapeutics in targeting tumor microenvironment for cancer therapy","volume":"126","author":"Muntimadugu","year":"2017","journal-title":"Pharmacol. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-019-1443-1","article-title":"Recent advances in nanotheranostics for triple negative breast cancer treatment","volume":"38","author":"Thakur","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Greish, K. (2010). Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Cancer Nanotechnology, Springer.","DOI":"10.1007\/978-1-60761-609-2_3"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/jso.21698","article-title":"The promise of nanotechnology for solving clinical problems in breast cancer","volume":"103","author":"Grobmyer","year":"2011","journal-title":"J. Surg. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"931","DOI":"10.7150\/thno.9663","article-title":"Progress in aptamer-mediated drug delivery vehicles for cancer targeting and its implications in addressing chemotherapeutic challenges","volume":"4","author":"Zhu","year":"2014","journal-title":"J. Theranostics"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2217\/nnm.14.19","article-title":"Nanomedicine for the treatment of triple-negative breast cancer","volume":"9","author":"Kutty","year":"2014","journal-title":"Nanomedicine"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1016\/j.biomaterials.2013.12.033","article-title":"The reduction of anti-cancer drug antagonism by the spatial protection of drugs with PLA\u2013TPGS nanoparticles","volume":"35","author":"Tan","year":"2014","journal-title":"Biomaterials"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.7150\/thno.38147","article-title":"Nanocarrier-based drug combination therapy for glioblastoma","volume":"10","author":"Zhao","year":"2020","journal-title":"Theranostics"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"10475","DOI":"10.1021\/acs.jmedchem.9b00511","article-title":"Precision cancer nanotherapy: Evolving role of multifunctional nanoparticles for cancer active targeting","volume":"62","author":"Ahmad","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"416","DOI":"10.2174\/1389200219666180918111528","article-title":"Cancer nanotechnology: A new revolution for cancer diagnosis and therapy","volume":"20","author":"Chaturvedi","year":"2019","journal-title":"Curr. Drug Metab."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Ali, E.S., Sharker, S.M., Islam, M.T., Khan, I.N., Shaw, S., Rahman, M.A., Uddin, S.J., Shill, M.C., Rehman, S., and Das, N. (2021). Targeting cancer cells with nanotherapeutics and nanodiagnostics: Current status and future perspectives. Seminars in Cancer Biology, Academic Press.","DOI":"10.1016\/j.semcancer.2020.01.011"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Su, S., and Kang, P.M. (2020). Recent Advances in Nanocarrier-Assisted Therapeutics Delivery Systems. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12090837"},{"key":"ref_36","first-page":"742","article-title":"Progress in Nanomedicine: Approved and Investigational Nanodrugs","volume":"42","author":"Ventola","year":"2017","journal-title":"P T A Peer-Rev. J. Formul. Manag."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2016.108","article-title":"Cancer nanomedicine: Progress, challenges and opportunities","volume":"17","author":"Shi","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1000164","DOI":"10.4172\/2157-7439.1000164","article-title":"Paclitaxel Nano-Delivery Systems: A Comprehensive Review","volume":"4","author":"Ma","year":"2013","journal-title":"J. Nanomed. Nanotechnol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"9449","DOI":"10.1007\/s00253-018-9352-3","article-title":"Nanomedicines for developing cancer nanotherapeutics: From benchtop to bedside and beyond","volume":"102","author":"Iqbal","year":"2018","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.coph.2020.09.012","article-title":"Recent developments in unraveling signaling mechanisms underlying drug resistance due to cancer stem-like cells","volume":"54","author":"Khan","year":"2020","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: An evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s43440-020-00138-7","article-title":"Drug resistance in cancer: Mechanisms and tackling strategies","volume":"72","author":"Haider","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"119667","DOI":"10.1016\/j.lfs.2021.119667","article-title":"Nanotherapeutic approach to tackle chemotherapeutic resistance of cancer stem cells","volume":"279","author":"Oliveira","year":"2021","journal-title":"Life Sci"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/carcin\/bgv067","article-title":"miR-27 is associated with chemoresistance in esophageal cancer through transformation of normal fibroblasts to cancer-associated fibroblasts","volume":"36","author":"Tanaka","year":"2015","journal-title":"Carcinogenesis"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/onc.2017.348","article-title":"Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP)","volume":"37","author":"Mitamura","year":"2018","journal-title":"Oncogene"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/jnci\/djj211","article-title":"Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer","volume":"98","author":"Kim","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.3892\/mmr.2014.3058","article-title":"Establishment and biological characteristics of acquired gefitinib resistance in cell line NCI-H1975\/gefinitib-resistant with epidermal growth factor receptor T790M mutation","volume":"11","author":"Zhao","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.15252\/emmm.201404914","article-title":"Intra-and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts","volume":"7","author":"Kemper","year":"2015","journal-title":"EMBO Mol. Med."},{"key":"ref_49","first-page":"6885","article-title":"Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds","volume":"52","author":"Meijer","year":"1992","journal-title":"Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"113959","DOI":"10.1016\/j.bcp.2020.113959","article-title":"Drug uptake-based chemoresistance in breast cancer treatment","volume":"177","author":"Muley","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12951-019-0560-5","article-title":"Engineered exosomes for targeted co-delivery of miR-21 inhibitor and chemotherapeutics to reverse drug resistance in colon cancer","volume":"18","author":"Liang","year":"2020","journal-title":"J. Nanobiotechnology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.clon.2020.03.005","article-title":"Targeting DNA repair in ovarian cancer treatment resistance","volume":"32","author":"Bowden","year":"2020","journal-title":"Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"199","DOI":"10.4149\/neo_2015_025","article-title":"Autophagy facilitates multidrug resistance development through inhibition of apoptosis in breast cancer cells","volume":"62","author":"Sun","year":"2015","journal-title":"Neoplasma"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Teeuwssen, M., and Fodde, R. (2019). Wnt signaling in ovarian cancer stemness, EMT, and therapy resistance. J. Clin. Med., 8.","DOI":"10.3390\/jcm8101658"},{"key":"ref_56","first-page":"1","article-title":"EMT-and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer","volume":"9","author":"Wang","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/9511","article-title":"Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo","volume":"5","author":"Sethi","year":"1999","journal-title":"Nat. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.phrs.2017.03.010","article-title":"Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas","volume":"120","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1097\/01.LAB.0000032411.41603.C2","article-title":"Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer","volume":"82","author":"Reinmuth","year":"2002","journal-title":"Lab. Investig."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.canlet.2015.07.044","article-title":"Tumor microenvironment and cancer therapy resistance","volume":"380","author":"Sun","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Shaw","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1158\/0008-5472.CAN-12-2217","article-title":"Intratumor heterogeneity: Evolution through space and time","volume":"72","author":"Swanton","year":"2012","journal-title":"Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3390\/cancers6031769","article-title":"Drug resistance in cancer: An overview","volume":"6","author":"Housman","year":"2014","journal-title":"Cancers"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1158\/1078-0432.CCR-05-2130","article-title":"Irinotecan inactivation is modulated by epigenetic silencing of UGT1A1 in colon cancer","volume":"12","author":"Gagnon","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Hughes, L.R., Stephens, T.C., Boyle, F.T., and Jackman, A.L. (1999). Raltitrexed (Tomudex TM), a highly polyglutamatable antifolate thymidylate synthase inhibitor. Antifolate Drugs in Cancer Therapy, Springer.","DOI":"10.1007\/978-1-59259-725-3_6"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"100","DOI":"10.5732\/cjc.011.10326","article-title":"Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology","volume":"31","author":"Xue","year":"2012","journal-title":"Chin. J. Cancer"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"djv222","DOI":"10.1093\/jnci\/djv222","article-title":"The role of multidrug resistance efflux pumps in cancer: Revisiting a JNCI publication exploring expression of the MDR1 (P-glycoprotein) gene","volume":"107","author":"Gottesman","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Bozzato, E., Bastiancich, C., and Pr\u00e9at, V.J.C. (2021). Nanomedicine: A Useful Tool against Glioma Stem Cells. Cancers, 13.","DOI":"10.3390\/cancers13010009"},{"key":"ref_69","first-page":"3269","article-title":"Bioactive nanotherapeutic trends to combat triple negative breast cancer","volume":"6","author":"Chowdhury","year":"2021","journal-title":"Bioact. Mater."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"14528","DOI":"10.1039\/C9NR04129J","article-title":"The pharmaceutical multi-activity of metallofullerenol invigorates cancer therapy","volume":"11","author":"Li","year":"2019","journal-title":"Nanoscale"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Nunes, T., Hamdan, D., Leboeuf, C., El Bouchtaoui, M., Gapihan, G., Nguyen, T.T., Meles, S., Angeli, E., Ratajczak, P., and Lu, H. (2018). Targeting cancer stem cells to overcome chemoresistance. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19124036"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.addr.2013.11.009","article-title":"Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology","volume":"66","author":"Bertrand","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0168-3659(99)00248-5","article-title":"Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review","volume":"65","author":"Maeda","year":"2000","journal-title":"J. Control. Release"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jconrel.2010.08.027","article-title":"To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery","volume":"148","author":"Danhier","year":"2010","journal-title":"J. Control. Release"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"CT224","DOI":"10.1158\/1538-7445.AM2014-CT224","article-title":"Abstract CT224: Pilot study in patients with advanced solid tumors to evaluate feasibility of ferumoxytol (FMX) as tumor imaging agent prior to MM-398, a nanoliposomal irinotecan (nal-IRI)","volume":"74","author":"Ramanathan","year":"2014","journal-title":"Cancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00280-014-2477-x","article-title":"High liposomal doxorubicin tumour tissue distribution, as determined by radiopharmaceutical labelling with 99m Tc-LD, is associated with the response and survival of patients with unresectable pleural mesothelioma treated with a combination of liposomal doxorubicin and cisplatin","volume":"74","author":"Arrieta","year":"2014","journal-title":"Cancer Chemother."},{"key":"ref_77","first-page":"99","article-title":"Peculiarities of apoptosis induction and cell metabolism in human ovarian carcinoma cell lines exposed to free and HPMA copolymer bound adriamycin","volume":"25","author":"Minko","year":"1998","journal-title":"Proc. Control. Release Soc."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0168-3659(98)00009-1","article-title":"HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line","volume":"54","author":"Minko","year":"1998","journal-title":"J. Control. Release"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jconrel.2015.10.012","article-title":"Nanotechnology for protein delivery: Overview and perspectives","volume":"240","author":"Yu","year":"2016","journal-title":"J. Control. Release"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl (CAELYX\u2122\/Doxil\u00ae) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer","volume":"15","author":"Wigler","year":"2004","journal-title":"Ann. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1007\/s40265-014-0291-8","article-title":"Albumin-bound paclitaxel: A review of its use for the first-line combination treatment of metastatic pancreatic cancer","volume":"74","author":"Hoy","year":"2014","journal-title":"Drugs"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.cytogfr.2019.02.001","article-title":"Folate-targeted immunotherapies: Passive and active strategies for cancer","volume":"45","author":"Farran","year":"2019","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.2147\/IJN.S234679","article-title":"Enhanced and prolonged antitumor effect of salinomycin-loaded gelatinase-responsive nanoparticles via targeted drug delivery and inhibition of cervical cancer stem cells","volume":"15","author":"Wang","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.msec.2019.04.065","article-title":"Targeting human brain cancer stem cells by curcumin-loaded nanoparticles grafted with anti-aldehyde dehydrogenase and sialic acid: Colocalization of ALDH and CD44","volume":"102","author":"Kuo","year":"2019","journal-title":"Mater. Sci. Eng. C"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"6855","DOI":"10.2147\/IJN.S181928","article-title":"Codelivery of doxorubicin and elacridar to target both liver cancer cells and stem cells by polylactide-co-glycolide\/d-alpha-tocopherol polyethylene glycol 1000 succinate nanoparticles","volume":"13","author":"Chen","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"19808","DOI":"10.1021\/acsami.9b04474","article-title":"Dual delivery of HNF4\u03b1 and cisplatin by mesoporous silica nanoparticles inhibits cancer pluripotency and tumorigenicity in hepatoma-derived CD133-expressing stem cells","volume":"11","author":"Tsai","year":"2019","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"102106","DOI":"10.1016\/j.nano.2019.102106","article-title":"Zileuton\u2122 loaded in polymer micelles effectively reduce breast cancer circulating tumor cells and intratumoral cancer stem cells","volume":"24","author":"Gener","year":"2020","journal-title":"Nanomed. Nanotechnol. Biol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1166\/jbn.2020.2991","article-title":"Superparamagnetic iron oxide nanoparticles induce ferroptosis of human ovarian cancer stem cells by weakening cellular autophagy","volume":"16","author":"Huang","year":"2020","journal-title":"J. Biomed. Nanotechnol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/j.nano.2018.05.015","article-title":"Targeted salinomycin delivery with EGFR and CD133 aptamers based dual-ligand lipid-polymer nanoparticles to both osteosarcoma cells and cancer stem cells","volume":"14","author":"Chen","year":"2018","journal-title":"Nanomed. Nanotechnol. Biol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.2147\/IJN.S260163","article-title":"A Novel Therapeutic siRNA Nanoparticle Designed for Dual-Targeting CD44 and Gli1 of Gastric Cancer Stem Cells","volume":"15","author":"Yao","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1166\/jnn.2018.14303","article-title":"MPEG-CS\/Bmi-1RNAi nanoparticles synthesis and its targeted inhibition effect on CD133+ laryngeal stem cells","volume":"18","author":"Wei","year":"2018","journal-title":"J. Nanosci. Nanotechnol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"055101","DOI":"10.1088\/1361-6528\/aaedd5","article-title":"Use of DNA-generated gold nanoparticles to radiosensitize and eradicate radioresistant glioma stem cells","volume":"30","author":"Kunoh","year":"2018","journal-title":"Nanotechnology"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1021\/acs.nanolett.8b00390","article-title":"Bioreducible polymeric nanoparticles containing multiplexed cancer stem cell regulating miRNAs inhibit glioblastoma growth and prolong survival","volume":"18","author":"Kozielski","year":"2018","journal-title":"Nano Lett."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1158\/0008-5472.CAN-18-2725","article-title":"Blockade of a laminin-411\u2013notch axis with CRISPR\/Cas9 or a nanobioconjugate inhibits glioblastoma growth through tumor-microenvironment cross-talk","volume":"79","author":"Sun","year":"2019","journal-title":"Cancer Res."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Heredia, J.M., and Carnero, A.J.C. (2020). Role of mitochondria in cancer stem cell resistance. Cells, 9.","DOI":"10.3390\/cells9071693"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"7173","DOI":"10.2147\/IJN.S221021","article-title":"Chitosan gold nanoparticles induce different ROS-dependent cell death modalities in leukemic cells","volume":"14","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Cordani, M., Strippoli, R., and Somoza, \u00c1.J.C. (2020). Nanomaterials as inhibitors of epithelial mesenchymal transition in cancer treatment. Cancers, 12.","DOI":"10.3390\/cancers12010025"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1002\/ijc.24890","article-title":"Sustained delivery and efficacy of polymeric nanoparticles containing osteopontin and bone sialoprotein antisenses in rats with breast cancer bone metastasis","volume":"126","author":"Elazar","year":"2010","journal-title":"Int. J. Cancer"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00280-013-2361-0","article-title":"A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors","volume":"73","author":"Tolcher","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature08956","article-title":"Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles","volume":"464","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"4141","DOI":"10.1200\/JCO.2013.55.0376","article-title":"First-in-human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors","volume":"32","author":"Schultheis","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"ra317","DOI":"10.1126\/scitranslmed.aad2355","article-title":"Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo","volume":"8","author":"Ashton","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1039\/C5BM00198F","article-title":"Biomaterials for mRNA delivery","volume":"3","author":"Islam","year":"2015","journal-title":"Biomater. Sci."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.jconrel.2015.07.030","article-title":"Using exosomes, naturally-equipped nanocarriers, for drug delivery","volume":"219","author":"Batrakova","year":"2015","journal-title":"J. Control. Release"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"ra128","DOI":"10.1126\/scitranslmed.3003651","article-title":"Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile","volume":"4","author":"Hrkach","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"15127","DOI":"10.1073\/pnas.1309566110","article-title":"Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle","volume":"110","author":"Eliasof","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"11449","DOI":"10.1073\/pnas.1411393111","article-title":"Correlating animal and human phase Ia\/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA","volume":"111","author":"Zuckerman","year":"2014","journal-title":"J. Proc. Natl."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1126\/science.1226338","article-title":"Multifunctional nanoparticles: Cost versus benefit of adding targeting and imaging capabilities","volume":"338","author":"Cheng","year":"2012","journal-title":"Science"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/jnci\/djm135","article-title":"Drug resistance and the solid tumor microenvironment","volume":"99","author":"Galmarini","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.drup.2012.01.006","article-title":"The tumor microenvironment is a dominant force in multidrug resistance","volume":"15","author":"Correia","year":"2012","journal-title":"Drug Resist. Updates"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s12307-009-0025-8","article-title":"The tumor microenvironment: The making of a paradigm","volume":"2","author":"Witz","year":"2009","journal-title":"Cancer Microenviron."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrc1098","article-title":"The pathogenesis of cancer metastasis: The\u2019seed and soil\u2019hypothesis revisited","volume":"3","author":"Fidler","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/wnan.1406","article-title":"Nanobiotechnology. Modifying the tumor microenvironment using nanoparticle therapeutics","volume":"8","author":"Roy","year":"2016","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Vaupel, P. (2004). Tumor microenvironmental physiology and its implications for radiation oncology. Seminars in Radiation Oncology, WB Saunders.","DOI":"10.1016\/j.semradonc.2004.04.008"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jconrel.2020.08.016","article-title":"Nano-therapeutics for modulating the tumour microenvironment: Design, development, and clinical translation","volume":"327","author":"Adityan","year":"2020","journal-title":"J. Control. Release"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1701156","DOI":"10.1002\/adhm.201701156","article-title":"Tumor microenvironment-enabled nanotherapy","volume":"7","author":"Wang","year":"2018","journal-title":"Adv. Healthc. Mater."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"11739","DOI":"10.1021\/acs.analchem.5b03131","article-title":"Aptamer\/graphene quantum dots nanocomposite capped fluorescent mesoporous silica nanoparticles for intracellular drug delivery and real-time monitoring of drug release","volume":"87","author":"Zheng","year":"2015","journal-title":"J. Anal. Chem."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"27885","DOI":"10.1021\/acsami.5b09934","article-title":"Multi-targeting peptide-functionalized nanoparticles recognized vasculogenic mimicry, tumor neovasculature, and glioma cells for enhanced anti-glioma therapy","volume":"7","author":"Feng","year":"2015","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.actbio.2019.09.009","article-title":"Tumor microenvironment targeted nanotherapeutics for cancer therapy and diagnosis: A review","volume":"101","author":"Thakkar","year":"2020","journal-title":"Acta Biomater."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jconrel.2009.03.010","article-title":"Targeted lipid-coated nanoparticles: Delivery of tumor necrosis factor-functionalized particles to tumor cells","volume":"137","author":"Messerschmidt","year":"2009","journal-title":"J. Control. Release"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jconrel.2015.03.023","article-title":"Targeting of metastasis-promoting tumor-associated fibroblasts and modulation of pancreatic tumor-associated stroma with a carboxymethylcellulose-docetaxel nanoparticle","volume":"206","author":"Ernsting","year":"2015","journal-title":"J. Control. Release"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jconrel.2012.01.014","article-title":"Cationic polyurethanes-short branch PEI-mediated delivery of Mir145 inhibited epithelial\u2013mesenchymal transdifferentiation and cancer stem-like properties and in lung adenocarcinoma","volume":"159","author":"Chiou","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"5915","DOI":"10.2147\/IJN.S36575","article-title":"FGF1-gold nanoparticle conjugates targeting FGFR efficiently decrease cell viability upon NIR irradiation","volume":"7","author":"Otlewski","year":"2012","journal-title":"Int. J. Nanomed."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/anie.201506262","article-title":"Transformable peptide nanocarriers for expeditious drug release and effective cancer therapy via cancer-associated fibroblast activation","volume":"55","author":"Ji","year":"2016","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1021\/acs.nanolett.6b04150","article-title":"Protein nanocage mediated fibroblast-activation protein targeted photoimmunotherapy to enhance cytotoxic T cell infiltration and tumor control","volume":"17","author":"Zhen","year":"2017","journal-title":"J. Nano Lett."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1172\/JCI120481","article-title":"Tumor stroma\u2013targeted antibody-drug conjugate triggers localized anticancer drug release","volume":"128","author":"Szot","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jconrel.2015.08.027","article-title":"Nanoparticle modulation of the tumor microenvironment enhances therapeutic efficacy of cisplatin","volume":"217","author":"Miao","year":"2015","journal-title":"J. Control. Release"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"4996","DOI":"10.1021\/nn5010815","article-title":"Co-delivery of cisplatin and rapamycin for enhanced anticancer therapy through synergistic effects and microenvironment modulation","volume":"8","author":"Guo","year":"2014","journal-title":"ACS Nano"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Kaps, L., and Schuppan, D.J.C. (2020). Targeting cancer associated fibroblasts in liver fibrosis and liver cancer using nanocarriers. Cells, 9.","DOI":"10.3390\/cells9092027"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s11095-010-0308-2","article-title":"Nanoparticulate delivery system targeted to tumor neovasculature for combined anticancer and antiangiogenesis therapy","volume":"28","author":"Wang","year":"2011","journal-title":"Pharm. Res."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.biomaterials.2012.10.048","article-title":"F3 peptide-functionalized PEG-PLA nanoparticles co-administrated with tLyp-1 peptide for anti-glioma drug delivery","volume":"34","author":"Hu","year":"2013","journal-title":"Biomaterials"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1021\/nn204625e","article-title":"In vivo targeting and imaging of tumor vasculature with radiolabeled, antibody-conjugated nanographene","volume":"6","author":"Hong","year":"2012","journal-title":"ACS Nano"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.2147\/IJN.S115357","article-title":"Noninvasive monitoring of early antiangiogenic therapy response in human nasopharyngeal carcinoma xenograft model using MRI with RGD-conjugated ultrasmall superparamagnetic iron oxide nanoparticles","volume":"11","author":"Cui","year":"2016","journal-title":"Int. J. Nanomed."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"9343","DOI":"10.1073\/pnas.0803728105","article-title":"Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis","volume":"105","author":"Murphy","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2147\/IJN.S28314","article-title":"RGD-conjugated gold nanorods induce radiosensitization in melanoma cancer cells by downregulating \u03b1v\u03b23 expression","volume":"7","author":"Fu","year":"2012","journal-title":"Int. J. Nanomed."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1021\/mp400216r","article-title":"Targeting of tumor-associated macrophages made possible by PEG-sheddable, mannose-modified nanoparticles","volume":"10","author":"Zhu","year":"2013","journal-title":"J Mol. Pharm."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1039\/C4NR03962A","article-title":"Biocompatible mannosylated endosomal-escape nanoparticles enhance selective delivery of short nucleotide sequences to tumor associated macrophages","volume":"7","author":"Ortega","year":"2015","journal-title":"Nanoscale"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1016\/j.biomaterials.2011.01.067","article-title":"Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery","volume":"32","author":"Zhang","year":"2011","journal-title":"Biomaterials"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-01830-8","article-title":"T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity","volume":"8","author":"Schmid","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"e122700","DOI":"10.1172\/jci.insight.122700","article-title":"Targeting antigen-presenting cells by anti\u2013PD-1 nanoparticles augments antitumor immunity","volume":"3","author":"Ordikhani","year":"2018","journal-title":"JCI Insight"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"955","DOI":"10.2217\/nnm-2018-0237","article-title":"Silencing PD-1 and PD-L1 with nanoparticle-delivered small interfering RNA increases cytotoxicity of tumor-infiltrating lymphocytes","volume":"14","author":"Wu","year":"2019","journal-title":"Nanomedicine"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms13193","article-title":"Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy","volume":"7","author":"Chen","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nnano.2017.57","article-title":"In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers","volume":"12","author":"Smith","year":"2017","journal-title":"Nat. Nanotechnol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1158\/2326-6066.CIR-17-0502","article-title":"CAR-T cells surface-engineered with drug-encapsulated nanoparticles can ameliorate intratumoral T-cell hypofunction","volume":"6","author":"Siriwon","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1016\/j.biomaterials.2013.12.027","article-title":"Selective eradication of tumor vascular pericytes by peptide-conjugated nanoparticles for antiangiogenic therapy of melanoma lung metastasis","volume":"35","author":"Guan","year":"2014","journal-title":"Biomaterials"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"415103","DOI":"10.1088\/0957-4484\/22\/41\/415103","article-title":"LyP-1-conjugated doxorubicin-loaded liposomes suppress lymphatic metastasis by inhibiting lymph node metastases and destroying tumor lymphatics","volume":"22","author":"Yan","year":"2011","journal-title":"Nanotechnology"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.biomaterials.2018.08.053","article-title":"Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophages","volume":"183","author":"Alsaab","year":"2018","journal-title":"Biomaterials"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"6643","DOI":"10.1158\/0008-5472.CAN-15-3475","article-title":"Hybrid manganese dioxide nanoparticles potentiate radiation therapy by modulating tumor hypoxia","volume":"76","author":"Abbasi","year":"2016","journal-title":"Cancer Res."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/j.biomaterials.2013.11.022","article-title":"Hypoxia-responsive polymeric nanoparticles for tumor-targeted drug delivery","volume":"35","author":"Thambi","year":"2014","journal-title":"Biomaterials"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"5766","DOI":"10.1039\/C9SC00985J","article-title":"An oxygen self-sufficient NIR-responsive nanosystem for enhanced PDT and chemotherapy against hypoxic tumors","volume":"10","author":"Yang","year":"2019","journal-title":"Chem. Sci."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jconrel.2015.11.017","article-title":"pH-responsive hybrid quantum dots for targeting hypoxic tumor siRNA delivery","volume":"220","author":"Zhu","year":"2015","journal-title":"J. Control. Release"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.2147\/OTT.S108169","article-title":"Tf-PEG-PLL-PLGA nanoparticles enhanced chemosensitivity for hypoxia-responsive tumor cells","volume":"9","author":"Liu","year":"2016","journal-title":"OncoTargets Ther."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"10992","DOI":"10.1021\/jacs.7b05559","article-title":"Continuous O2-evolving MnFe2O4 nanoparticle-anchored mesoporous silica nanoparticles for efficient photodynamic therapy in hypoxic cancer","volume":"139","author":"Kim","year":"2017","journal-title":"J. Am. Chem. Soc."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.ijbiomac.2017.11.048","article-title":"Carboxymethyl dextran-based hypoxia-responsive nanoparticles for doxorubicin delivery","volume":"110","author":"Son","year":"2018","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1703197","DOI":"10.1002\/adfm.201703197","article-title":"Cancer cell membrane-biomimetic oxygen nanocarrier for breaking hypoxia-induced chemoresistance","volume":"27","author":"Tian","year":"2017","journal-title":"Adv. Funct. Mater."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"8674","DOI":"10.1158\/0008-5472.CAN-10-1917","article-title":"F3-targeted cisplatin-hydrogel nanoparticles as an effective therapeutic that targets both murine and human ovarian tumor endothelial cells in vivo","volume":"70","author":"Winer","year":"2010","journal-title":"Cancer Res."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1021\/nn200007z","article-title":"Doxorubicin-tethered responsive gold nanoparticles facilitate intracellular drug delivery for overcoming multidrug resistance in cancer cells","volume":"5","author":"Wang","year":"2011","journal-title":"ACS Nano"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/21691401.2017.1290648","article-title":"Delivery of curcumin by a pH-responsive chitosan mesoporous silica nanoparticles for cancer treatment","volume":"46","author":"Beygzadeh","year":"2018","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.actbio.2017.11.010","article-title":"Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy","volume":"66","author":"Liu","year":"2018","journal-title":"Acta Biomater."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.actbio.2017.11.007","article-title":"Lectin-conjugated pH-responsive mesoporous silica nanoparticles for targeted bone cancer treatment","volume":"65","author":"Lozano","year":"2018","journal-title":"Acta Biomater."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"6753","DOI":"10.1021\/acsnano.6b02326","article-title":"Smart superstructures with ultrahigh pH-sensitivity for targeting acidic tumor microenvironment: Instantaneous size switching and improved tumor penetration","volume":"10","author":"Li","year":"2016","journal-title":"ACS Nano"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/696835","article-title":"A pH-sensitive, biobased calcium carbonate aragonite nanocrystal as a novel anticancer delivery system","volume":"2013","author":"Ismail","year":"2013","journal-title":"BioMed Res. Int."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1021\/acs.nanolett.8b04296","article-title":"Nanoenabled modulation of acidic tumor microenvironment reverses anergy of infiltrating T cells and potentiates anti-PD-1 therapy","volume":"19","author":"Zhang","year":"2019","journal-title":"Nano Lett."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep21629","article-title":"Glucose is a key driver for GLUT1-mediated nanoparticles internalization in breast cancer cells","volume":"6","author":"Venturelli","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"E5328","DOI":"10.1073\/pnas.1611406113","article-title":"Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer","volume":"113","author":"Elgogary","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1039\/C4SC01963F","article-title":"The energy blocker inside the power house: Mitochondria targeted delivery of 3-bromopyruvate","volume":"6","author":"Marrache","year":"2015","journal-title":"Chem. Sci."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"24075","DOI":"10.1021\/acsami.5b07116","article-title":"Hybrid collagenase nanocapsules for enhanced nanocarrier penetration in tumoral tissues","volume":"7","author":"Villegas","year":"2015","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"11008","DOI":"10.1021\/acsnano.9b02395","article-title":"Collagenase nanoparticles enhance the penetration of drugs into pancreatic tumors","volume":"13","author":"Zinger","year":"2019","journal-title":"J. ACS Nano"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/978-3-319-16555-4_9","article-title":"Exploring the tumor microenvironment with nanoparticles","volume":"166","author":"Miao","year":"2015","journal-title":"Nanotechnol. -Based Precis. Tools Detect. Treat. Cancer"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ejps.2012.12.006","article-title":"A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics","volume":"48","author":"Steichen","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s12035-012-8244-2","article-title":"Neurovascular unit: A focus on pericytes","volume":"45","author":"Brites","year":"2012","journal-title":"Mol. Neurobiol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejpb.2015.03.018","article-title":"Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy","volume":"93","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/nm.4409","article-title":"Cancer stem cells revisited","volume":"23","author":"Batlle","year":"2017","journal-title":"Nat. Med."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrclinonc.2017.44","article-title":"EMT, CSCs, and drug resistance: The mechanistic link and clinical implications","volume":"14","author":"Shibue","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.biocel.2018.08.011","article-title":"Role of tumor microenvironment in cancer stem cell chemoresistance and recurrence","volume":"103","author":"Das","year":"2018","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"8381","DOI":"10.1002\/jcp.27740","article-title":"Cancer stem cells (CSCs) in cancer progression and therapy","volume":"234","author":"Najafi","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"116781","DOI":"10.1016\/j.lfs.2019.116781","article-title":"Cancer stem cell (CSC) resistance drivers","volume":"234","author":"Najafi","year":"2019","journal-title":"Life Sci."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.2147\/IJN.S321416","article-title":"Nanoparticle-mediated targeted drug delivery to remodel tumor microenvironment for cancer therapy","volume":"16","author":"Tang","year":"2021","journal-title":"Int. J. Nanomed."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.gene.2018.09.052","article-title":"Cancer stem cells: A brief review of the current status","volume":"681","year":"2019","journal-title":"Gene"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"5725","DOI":"10.1021\/nn506928p","article-title":"Chitosan-decorated doxorubicin-encapsulated nanoparticle targets and eliminates tumor reinitiating cancer stem-like cells","volume":"9","author":"Rao","year":"2015","journal-title":"ACS Nano"},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Prieto-Vila, M., Takahashi, R.-U., Usuba, W., Kohama, I., and Ochiya, T. (2017). Drug resistance driven by cancer stem cells and their niche. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18122574"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/nmeth.3112","article-title":"Intracellular autofluorescence: A biomarker for epithelial cancer stem cells","volume":"11","author":"Dorado","year":"2014","journal-title":"Nat. Methods"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1002\/smll.201601932","article-title":"Microenvironment-Responsive Three-Pronged Approach Breaking Traditional Chemotherapy to Target Cancer Stem Cells for Synergistic Inoperable Large Tumor Therapy","volume":"12","author":"Li","year":"2016","journal-title":"Small"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41565-020-00793-0","article-title":"A nanotherapeutic strategy to overcome chemotherapeutic resistance of cancer stem-like cells","volume":"16","author":"Shen","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"305707","DOI":"10.1088\/1361-6528\/ab8593","article-title":"CD271 antibody-functionalized HGNs for targeted photothermal therapy of osteosarcoma stem cells","volume":"31","author":"Tian","year":"2020","journal-title":"Nanotechnology"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.2147\/IJN.S197265","article-title":"A novel theranostic gold nanorods-and Adriamycin-loaded micelle for EpCAM targeting, laser ablation, and photoacoustic imaging of cancer stem cells in hepatocellular carcinoma","volume":"14","author":"Locatelli","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"118152","DOI":"10.1016\/j.lfs.2020.118152","article-title":"Electrospun composite nanofibers with all-trans retinoic acid and MWCNTs-OH against cancer stem cells","volume":"258","author":"Chen","year":"2020","journal-title":"Life Sci"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"16031","DOI":"10.1021\/acsami.9b23177","article-title":"Melanoma cell membrane biomimetic versatile CuS nanoprobes for homologous targeting photoacoustic imaging and photothermal chemotherapy","volume":"12","author":"Wu","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"14066","DOI":"10.1002\/anie.201814098","article-title":"Enhancement of photodynamic cancer therapy by physical and chemical factors","volume":"58","author":"Yang","year":"2019","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"6827","DOI":"10.2147\/IJN.S269321","article-title":"Pathological Mechanism of Photodynamic Therapy and Photothermal Therapy Based on Nanoparticles","volume":"15","author":"Hou","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"ref_191","doi-asserted-by":"crossref","unstructured":"Crous, A., and Abrahamse, H. (2020). Effective gold nanoparticle-antibody-mediated drug delivery for photodynamic therapy of lung cancer stem cells. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21113742"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"6476","DOI":"10.1039\/C9TB01299K","article-title":"Combinatorial photochemotherapy on liver cancer stem cells with organoplatinum (ii) metallacage-based nanoparticles","volume":"7","author":"Yang","year":"2019","journal-title":"J. Mater. Chem. B"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"6511","DOI":"10.1039\/C7NR09717D","article-title":"Theranostic micelles based on upconversion nanoparticles for dual-modality imaging and photodynamic therapy in hepatocellular carcinoma","volume":"10","author":"Han","year":"2018","journal-title":"Nanoscale"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1039\/C9NR07947E","article-title":"MnO 2@ Ce6-loaded mesenchymal stem cells as an \u201coxygen-laden guided-missile\u201d for the enhanced photodynamic therapy on lung cancer","volume":"12","author":"Cao","year":"2020","journal-title":"Nanoscale"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.msec.2019.01.038","article-title":"Comparative evaluation of magnetic hyperthermia performance and biocompatibility of magnetite and novel Fe-doped hardystonite nanoparticles for potential bone cancer therapy","volume":"98","author":"Farzin","year":"2019","journal-title":"Mater. Sci. Eng. C"},{"key":"ref_196","doi-asserted-by":"crossref","unstructured":"Ghorbanzade, S., Naghib, S.M., Sadr, A., Fateminia, F.S., Ghaffarinejad, A., Majidzadeh-A, K., and Sanati-Nezhad, A. (2019). Multifunctional magnetic nanoparticles-labeled mesenchymal stem cells for hyperthermia and bioimaging applications. Stem Cell Nanotechnology, Springer.","DOI":"10.1007\/7651_2019_271"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"7549","DOI":"10.2147\/IJN.S215087","article-title":"CD44-targeted magnetic nanoparticles kill head and neck squamous cell carcinoma stem cells in an alternating magnetic field","volume":"14","author":"Su","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.ymthe.2019.04.018","article-title":"Delivery of anti-miRNA for triple-negative breast cancer therapy using RNA nanoparticles targeting stem cell marker CD133","volume":"27","author":"Yin","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ymthe.2017.11.006","article-title":"Blocking stemness and metastatic properties of ovarian cancer cells by targeting p70S6K with dendrimer nanovector-based siRNA delivery","volume":"26","author":"Ma","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/path.2993","article-title":"Silencing disease genes in the laboratory and the clinic","volume":"226","author":"Watts","year":"2012","journal-title":"J. Pathol."},{"key":"ref_201","doi-asserted-by":"crossref","unstructured":"Hattab, D., Gazzali, A.M., and Bakhtiar, A.J.P. (2021). Clinical advances of siRNA-based nanotherapeutics for cancer treatment. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13071009"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.nantod.2015.06.008","article-title":"15 years on siRNA delivery: Beyond the state-of-the-art on inorganic nanoparticles for RNAi therapeutics","volume":"10","author":"Conde","year":"2015","journal-title":"Nano Today"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nrd2742","article-title":"Knocking down barriers: Advances in siRNA delivery","volume":"8","author":"Whitehead","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jconrel.2011.09.063","article-title":"Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress","volume":"161","author":"Lammers","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_205","doi-asserted-by":"crossref","unstructured":"Roscigno, G., Scognamiglio, I., Ingenito, F., Chianese, R.V., Palma, F., Chan, A., and Condorelli, G.J.C. (2020). Modulating the crosstalk between the tumor and the microenvironment using sirna: A flexible strategy for breast cancer treatment. Cancers, 12.","DOI":"10.3390\/cancers12123744"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1517\/17425247.2016.1134486","article-title":"Progress and perspective of inorganic nanoparticle-based siRNA delivery systems","volume":"13","author":"Jiang","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1096\/fj.201700629R","article-title":"Targeting the Stat6 pathway in tumor-associated macrophages reduces tumor growth and metastatic niche formation in breast cancer","volume":"32","author":"Bansal","year":"2018","journal-title":"FASEB J."},{"key":"ref_208","doi-asserted-by":"crossref","unstructured":"Egorova, A.A., Shtykalova, S.V., Maretina, M.A., Sokolov, D.I., Selkov, S.A., Baranov, V.S., and Kiselev, A.V. (2019). Synergistic anti-angiogenic effects using peptide-based combinatorial delivery of siRNAs targeting VEGFA, VEGFR1, and endoglin genes. Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11060261"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.canlet.2020.06.019","article-title":"Endothelial cells under therapy-induced senescence secrete CXCL11, which increases aggressiveness of breast cancer cells","volume":"490","author":"Hwang","year":"2020","journal-title":"Cancer Lett."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.bbamem.2006.03.020","article-title":"Assembly of nucleic acid-lipid nanoparticles from aqueous-organic monophases","volume":"1758","author":"Hayes","year":"2006","journal-title":"Biochim. Et Biophys. Acta Biomembr."},{"key":"ref_211","doi-asserted-by":"crossref","unstructured":"Mainini, F., and Eccles, M.R. (2020). Lipid and polymer-based nanoparticle siRNA delivery systems for cancer therapy. Molecules, 25.","DOI":"10.3390\/molecules25112692"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"9571","DOI":"10.1021\/nn4047925","article-title":"Layer-by-layer nanoparticles for systemic codelivery of an anticancer drug and siRNA for potential triple-negative breast cancer treatment","volume":"7","author":"Deng","year":"2013","journal-title":"ACS Nano"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.canlet.2013.09.037","article-title":"Polymeric micelles containing reversibly phospholipid-modified anti-survivin siRNA: A promising strategy to overcome drug resistance in cancer","volume":"343","author":"Salzano","year":"2014","journal-title":"Cancer Lett."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1021\/nn505729m","article-title":"\u201cTriple-punch\u201d strategy for triple negative breast cancer therapy with minimized drug dosage and improved antitumor efficacy","volume":"9","author":"Su","year":"2015","journal-title":"Acs Nano"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"16619","DOI":"10.18632\/oncotarget.7672","article-title":"FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells","volume":"7","author":"Hamurcu","year":"2016","journal-title":"Oncotarget"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"96826","DOI":"10.18632\/oncotarget.18281","article-title":"Microfluidic hydrodynamic focusing synthesis of polymer-lipid nanoparticles for siRNA delivery","volume":"8","author":"Huang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"26613","DOI":"10.1021\/acsami.6b09991","article-title":"Delivery of siRNA using lipid nanoparticles modified with cell penetrating peptide","volume":"8","author":"Li","year":"2016","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1021\/acs.molpharmaceut.7b00362","article-title":"Efficient siRNA delivery by lipid nanoparticles modified with a nonstandard macrocyclic peptide for EpCAM-targeting","volume":"14","author":"Sakurai","year":"2017","journal-title":"Mol. Pharm."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.2217\/nnm-2017-0081","article-title":"Modified gold-based siRNA nanotherapeutics for targeted therapy of triple-negative breast cancer","volume":"12","author":"Shahbazi","year":"2017","journal-title":"Nanomedicine"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1007\/s00277-019-03713-y","article-title":"Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo","volume":"98","author":"Jyotsana","year":"2019","journal-title":"Ann. Hematol."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/s41565-019-0381-6","article-title":"Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer","volume":"14","author":"Xu","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1158\/1535-7163.MCT-16-0644","article-title":"Targeted treatment of metastatic breast cancer by PLK1 siRNA delivered by an antioxidant nanoparticle platform","volume":"16","author":"Morry","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1158\/0008-5472.CAN-17-2388","article-title":"Selective mTORC2 inhibitor therapeutically blocks breast cancer cell growth and survival","volume":"78","author":"Werfel","year":"2018","journal-title":"Cancer Res."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1021\/acs.molpharmaceut.7b01055","article-title":"Systemic administration of siRNA with anti-HB-EGF antibody-modified lipid nanoparticles for the treatment of triple-negative breast cancer","volume":"15","author":"Okamoto","year":"2018","journal-title":"Mol. Pharm."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"eaax5032","DOI":"10.1126\/sciadv.aax5032","article-title":"Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer","volume":"6","author":"Huang","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1089\/nat.2011.0312","article-title":"Local delivery of chitosan\/VEGF siRNA nanoplexes reduces angiogenesis and growth of breast cancer in vivo","volume":"22","author":"Kabasakal","year":"2012","journal-title":"Nucleic Acid Ther."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7150\/thno.12167","article-title":"ICAM-1-targeted, Lcn2 siRNA-encapsulating liposomes are potent anti-angiogenic agents for triple negative breast cancer","volume":"6","author":"Guo","year":"2016","journal-title":"Theranostics"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1021\/acs.bioconjchem.9b00028","article-title":"Systemic delivery of tumor-targeting siRNA nanoparticles against an oncogenic LncRNA facilitates effective triple-negative breast cancer therapy","volume":"30","author":"Vaidya","year":"2019","journal-title":"Bioconjugate Chem."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.2217\/nnm-2019-0132","article-title":"EF2-kinase targeted cobalt-ferrite siRNA-nanotherapy suppresses BRCA1-mutated breast cancer","volume":"14","author":"Asik","year":"2019","journal-title":"Nanomedicine"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.2174\/0929867054020981","article-title":"Overview of ribonucleotide reductase inhibitors: An appealing target in anti-tumour therapy","volume":"12","author":"Cerqueira","year":"2005","journal-title":"Curr. Med. Chem."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"24560","DOI":"10.18632\/oncotarget.4183","article-title":"RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients","volume":"6","author":"Golan","year":"2015","journal-title":"Oncotarget"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"11006","DOI":"10.1200\/jco.2015.33.15_suppl.11006","article-title":"Safety and activity of DCR-MYC, a first-in-class Dicer-substrate small interfering RNA (DsiRNA) targeting MYC, in a phase I study in patients with advanced solid tumors","volume":"33","author":"Tolcher","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1177\/0192623316645860","article-title":"Preclinical safety evaluation in rats of a polymeric matrix containing an siRNA drug used as a local and prolonged delivery system for pancreatic cancer therapy","volume":"44","author":"Ramot","year":"2016","journal-title":"Toxicol. Pathol."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"e99263","DOI":"10.1172\/jci.insight.99263","article-title":"Generation and testing of clinical-grade exosomes for pancreatic cancer","volume":"3","author":"Mendt","year":"2018","journal-title":"JCI Insight"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.2147\/IJN.S106625","article-title":"Lipid nanoparticles for targeted siRNA delivery\u2013going from bench to bedside","volume":"11","author":"Zatsepin","year":"2016","journal-title":"Int. J. Nanomed."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1158\/1535-7163.MCT-16-0541","article-title":"Preclinical mammalian safety studies of EPHARNA (DOPC nanoliposomal EphA2-targeted siRNA)","volume":"16","author":"Wagner","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"105159","DOI":"10.1016\/j.ejps.2019.105159","article-title":"Lipid-based nanocarriers for delivery of small interfering RNA for therapeutic use","volume":"142","author":"Parashar","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.tranon.2015.03.010","article-title":"Targeting polo-like kinases: A promising therapeutic approach for cancer treatment","volume":"8","author":"Liu","year":"2015","journal-title":"Transl. Oncol."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.phrs.2016.11.014","article-title":"Tumor-targeted nanomedicines for cancer theranostics","volume":"115","author":"Arranja","year":"2017","journal-title":"Pharmacol. Res."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/2159-8290.CD-12-0429","article-title":"First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement","volume":"3","author":"Tabernero","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.2147\/IJN.S164355","article-title":"Global trends in nanomedicine research on triple negative breast cancer: A bibliometric analysis","volume":"13","author":"Teles","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1080\/21691401.2017.1307210","article-title":"Advances in siRNA delivery in cancer therapy","volume":"46","author":"Singh","year":"2018","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"281","DOI":"10.7150\/thno.35568","article-title":"RNA nanotechnology-mediated cancer immunotherapy","volume":"10","author":"Lin","year":"2020","journal-title":"Theranostics"},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.7150\/ijbs.47203","article-title":"miRNA-based biomarkers, therapies, and resistance in Cancer","volume":"16","author":"He","year":"2020","journal-title":"Int. J. Biol. Sci."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"12369","DOI":"10.1002\/jcp.28058","article-title":"MicroRNA replacement therapy in cancer","volume":"234","author":"Mollaei","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.critrevonc.2015.10.003","article-title":"Exploring miRNA based approaches in cancer diagnostics and therapeutics","volume":"98","author":"Mishra","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.2174\/1381612823666170714151715","article-title":"MiRNA-based therapeutics for lung cancer","volume":"23","author":"Wu","year":"2017","journal-title":"Curr. Pharm. Des."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s13346-013-0160-0","article-title":"Overcoming obstacles in microRNA delivery towards improved cancer therapy","volume":"4","author":"Markovsky","year":"2014","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_249","doi-asserted-by":"crossref","unstructured":"Tivnan, A., Orr, W.S., Gubala, V., Nooney, R., Williams, D.E., McDonagh, C., Prenter, S., Harvey, H., Domingo-Fern\u00e1ndez, R., and Bray, I.M. (2012). Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0038129"},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.biomaterials.2012.10.023","article-title":"A gold nanoparticle platform for the delivery of functional microRNAs into cancer cells","volume":"34","author":"Ghosh","year":"2013","journal-title":"Biomaterials"},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1158\/0008-5472.CAN-10-4645","article-title":"MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma","volume":"71","author":"Ibrahim","year":"2011","journal-title":"Cancer Res."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.addr.2014.09.010","article-title":"Combination of microRNA therapeutics with small-molecule anticancer drugs: Mechanism of action and co-delivery nanocarriers","volume":"81","author":"Dai","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jconrel.2014.09.001","article-title":"Nanocarrier mediated delivery of siRNA\/miRNA in combination with chemotherapeutic agents for cancer therapy: Current progress and advances","volume":"194","author":"Gandhi","year":"2014","journal-title":"J. Control. Release"},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jconrel.2014.09.005","article-title":"Dual drugs (microRNA-34a and paclitaxel)-loaded functional solid lipid nanoparticles for synergistic cancer cell suppression","volume":"194","author":"Shi","year":"2014","journal-title":"J. Control. Release"},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"7077","DOI":"10.1016\/j.biomaterials.2014.04.053","article-title":"Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer","volume":"35","author":"Mittal","year":"2014","journal-title":"Biomaterials"},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"7573","DOI":"10.1158\/0008-5472.CAN-14-1140","article-title":"Targeting of miR34a\u2013NOTCH1 axis reduced breast cancer stemness and chemoresistance","volume":"74","author":"Park","year":"2014","journal-title":"Cancer Res."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3389\/fgene.2018.00174","article-title":"Screen for MicroRNA and drug interactions in breast cancer cell lines points to miR-126 as a modulator of CDK4\/6 and PIK3CA inhibitors","volume":"9","author":"Baldassari","year":"2018","journal-title":"Front. Genet."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1016\/j.biomaterials.2013.11.039","article-title":"Star-branched amphiphilic PLA-b-PDMAEMA copolymers for co-delivery of miR-21 inhibitor and doxorubicin to treat glioma","volume":"35","author":"Qian","year":"2014","journal-title":"Biomaterials"},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-019-1082-9","article-title":"miR-149 inhibits cell proliferation and enhances chemosensitivity by targeting CDC42 and BCL2 in neuroblastoma","volume":"19","author":"Mao","year":"2019","journal-title":"Cancer Cell Int."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.biocel.2019.01.020","article-title":"MicroRNA-137 inhibits autophagy and chemosensitizes pancreatic cancer cells by targeting ATG5","volume":"111","author":"Wang","year":"2019","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.omtn.2019.10.045","article-title":"Therapeutic potential of LNP-mediated delivery of miR-634 for cancer therapy","volume":"19","author":"Gokita","year":"2020","journal-title":"Mol. Ther. -Nucleic Acids"},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"e112200","DOI":"10.1371\/journal.pone.0112200","article-title":"PSMA ligand conjugated PCL-PEG polymeric micelles targeted to prostate cancer cells","volume":"9","author":"Jin","year":"2014","journal-title":"PLoS ONE"},{"key":"ref_263","first-page":"500","article-title":"Aptamer-mediated selective delivery of short RNA therapeutics in cancer cells","volume":"10","author":"Esposito","year":"2014","journal-title":"J. RNAi Gene Silencing Int. J. RNA"},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"zcab030","DOI":"10.1093\/narcan\/zcab030","article-title":"Ligand-mediated delivery of RNAi-based therapeutics for the treatment of oncological diseases","volume":"3","author":"Abdelaal","year":"2021","journal-title":"NAR Cancer"},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1021\/acs.jmedchem.7b01407","article-title":"Salutaxel, a conjugate of docetaxel and a muramyl dipeptide (MDP) analogue, acts as multifunctional prodrug that inhibits tumor growth and metastasis","volume":"61","author":"Wen","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.actbio.2020.05.026","article-title":"Self-assembling prodrug nanotherapeutics for synergistic tumor targeted drug delivery","volume":"111","author":"Wang","year":"2020","journal-title":"Acta Biomater."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"E217","DOI":"10.1073\/pnas.1313459110","article-title":"A unique squalenoylated and nonpegylated doxorubicin nanomedicine with systemic long-circulating properties and anticancer activity","volume":"111","author":"Maksimenko","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"6638","DOI":"10.1039\/C7CS00521K","article-title":"Self-assembling prodrugs","volume":"46","author":"Cheetham","year":"2017","journal-title":"Chem. Soc. Rev."},{"key":"ref_269","doi-asserted-by":"crossref","unstructured":"Wang, Q., Xiao, M., Wang, D., Hou, X., Gao, J., Liu, J., and Liu, J. (2021). In Situ Supramolecular Self-Assembly of Pt (IV) Prodrug to Conquer Cisplatin Resistance. Adv. Funct. Mater., 2101826.","DOI":"10.1002\/adfm.202101826"},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jconrel.2005.09.034","article-title":"Block copolymer micelles: Preparation, characterization and application in drug delivery","volume":"109","author":"Gaucher","year":"2005","journal-title":"J. Control. Release"},{"key":"ref_271","doi-asserted-by":"crossref","unstructured":"Zhang, P., Xu, J., Gao, S.E., and Li, S. (2016). Dual-function nanocarriers with interfacial drug-interactive motifs for improved delivery of chemotherapeutic agents. Nanobiomaterials in Cancer Therapy, Elsevier.","DOI":"10.1016\/B978-0-323-42863-7.00012-8"},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1021\/bc3000468","article-title":"PEG-derivatized embelin as a dual functional carrier for the delivery of paclitaxel","volume":"23","author":"Huang","year":"2012","journal-title":"Bioconjugate Chem."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1208\/s12248-014-9651-2","article-title":"Fmoc-conjugated PEG-vitamin E 2 micelles for tumor-targeted delivery of paclitaxel: Enhanced drug-carrier interaction and loading capacity","volume":"16","author":"Zhang","year":"2014","journal-title":"AAPS J."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"425103","DOI":"10.1088\/0957-4484\/27\/42\/425103","article-title":"Disulfide-crosslinked nanomicelles confer cancer-specific drug delivery and improve efficacy of paclitaxel in bladder cancer","volume":"27","author":"Pan","year":"2016","journal-title":"Nanotechnology"},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-01651-9","article-title":"Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression","volume":"8","author":"Lu","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"11041","DOI":"10.1021\/acsnano.8b05189","article-title":"Breast cancer chemo-immunotherapy through liposomal delivery of an immunogenic cell death stimulus plus interference in the IDO-1 pathway","volume":"12","author":"Lu","year":"2018","journal-title":"ACS Nano"},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1021\/bc400326y","article-title":"Self-assembling doxorubicin\u2013tocopherol succinate prodrug as a new drug delivery system: Synthesis, characterization, and in vitro and in vivo anticancer activity","volume":"25","author":"Duhem","year":"2014","journal-title":"Bioconjugate Chem."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1002\/adhm.201600345","article-title":"Self-Assembling Doxorubicin Prodrug Forming Nanoparticles and Effectively Reversing Drug Resistance In Vitro and In Vivo","volume":"5","author":"Mao","year":"2016","journal-title":"Adv. Healthc. Mater."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"119751","DOI":"10.1016\/j.biomaterials.2019.119751","article-title":"The novel platinum (IV) prodrug with self-assembly property and structure-transformable character against triple-negative breast cancer","volume":"232","author":"Yang","year":"2020","journal-title":"Biomaterials"},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"1703135","DOI":"10.1002\/adma.201703135","article-title":"Self-assembly of an amphiphilic janus camptothecin\u2013floxuridine conjugate into liposome-like nanocapsules for more efficacious combination chemotherapy in cancer","volume":"29","author":"Liang","year":"2017","journal-title":"Adv. Mater."},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"8005","DOI":"10.1021\/jacs.8b04400","article-title":"Supramolecular polymer-based nanomedicine: High therapeutic performance and negligible long-term immunotoxicity","volume":"140","author":"Yu","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2019.07.003","article-title":"Exosomes and their role in tumorigenesis and anticancer drug resistance","volume":"45","author":"Milman","year":"2019","journal-title":"Drug Resist. Updates"},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.bbcan.2018.07.003","article-title":"Extracellular vesicles and anti-cancer drug resistance","volume":"1870","year":"2018","journal-title":"Biochim. Et Biophys. Acta -Rev. Cancer"},{"key":"ref_284","first-page":"2985","article-title":"The emerging role of exosomes in cancer chemoresistance","volume":"9","author":"Li","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-020-03189-z","article-title":"Exosomes and breast cancer drug resistance","volume":"11","author":"Dong","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jconrel.2019.12.023","article-title":"The role of liposomes in clinical nanomedicine development. What now? Now what?","volume":"318","author":"Crommelin","year":"2020","journal-title":"J. Control. Release"},{"key":"ref_287","doi-asserted-by":"crossref","unstructured":"Wang, T.-T., Xia, Y.-Y., Gao, J.-Q., Xu, D.-H., and Han, M. (2021). Recent Progress in the Design and Medical Application of In Situ Self-Assembled Polypeptide Materials. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13050753"},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1038\/ng.3967","article-title":"Patient-derived xenografts undergo mouse-specific tumor evolution","volume":"49","author":"Ha","year":"2017","journal-title":"Nat. Genet."},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3389\/fphar.2016.00533","article-title":"Exosome-based cancer therapy: Implication for targeting cancer stem cells","volume":"7","author":"Wang","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s10571-015-0280-9","article-title":"Exosomes as tools to suppress primary brain tumor","volume":"36","author":"Katakowski","year":"2016","journal-title":"Cell. Mol. Neurobiol."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/aps.2017.12","article-title":"Engineering exosomes as refined biological nanoplatforms for drug delivery","volume":"38","author":"Luan","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.molmed.2018.01.006","article-title":"Manufacturing exosomes: A promising therapeutic platform","volume":"24","author":"Colao","year":"2018","journal-title":"Trends Mol. Med."},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.canlet.2015.10.020","article-title":"Bovine milk-derived exosomes for drug delivery","volume":"371","author":"Munagala","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"31761","DOI":"10.1074\/jbc.M113.514091","article-title":"P-glycoprotein mediates drug resistance via a novel mechanism involving lysosomal sequestration","volume":"288","author":"Yamagishi","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.nano.2015.10.012","article-title":"Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells","volume":"12","author":"Kim","year":"2016","journal-title":"Nanomed. Nanotechnol. Biol."},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"7698","DOI":"10.1021\/nn402232g","article-title":"Bioinspired exosome-mimetic nanovesicles for targeted delivery of chemotherapeutics to malignant tumors","volume":"7","author":"Jang","year":"2013","journal-title":"ACS Nano"},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jconrel.2015.09.031","article-title":"Microvesicle-and exosome-mediated drug delivery enhances the cytotoxicity of Paclitaxel in autologous prostate cancer cells","volume":"220","author":"Saari","year":"2015","journal-title":"J. Control. Release"},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep38541","article-title":"Nanosomes carrying doxorubicin exhibit potent anticancer activity against human lung cancer cells","volume":"6","author":"Srivastava","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_299","doi-asserted-by":"crossref","unstructured":"Sinha, D., Roy, S., Saha, P., Chatterjee, N., and Bishayee, A. (2021). Trends in research on exosomes in cancer progression and anticancer therapy. Cancers, 13.","DOI":"10.3390\/cancers13020326"},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-020-02962-4","article-title":"Bone marrow mesenchymal stem cells-derived exosomal microRNA-193a reduces cisplatin resistance of non-small cell lung cancer cells via targeting LRRC1","volume":"11","author":"Wu","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1478-811X-11-88","article-title":"Exosomes are natural carriers of exogenous siRNA to human cells in vitro","volume":"11","author":"Shtam","year":"2013","journal-title":"Cell Commun. Signal."},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/nature22341","article-title":"Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer","volume":"546","author":"Kamerkar","year":"2017","journal-title":"Nature"},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/cas.13488","article-title":"Exosomes serve as nanoparticles to suppress tumor growth and angiogenesis in gastric cancer by delivering hepatocyte growth factor si RNA","volume":"109","author":"Zhang","year":"2018","journal-title":"Cancer Sci."},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-015-0220-7","article-title":"Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma","volume":"8","author":"Lou","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-019-1512-5","article-title":"MiR-199a-modified exosomes from adipose tissue-derived mesenchymal stem cells improve hepatocellular carcinoma chemosensitivity through mTOR pathway","volume":"39","author":"Lou","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jconrel.2017.09.013","article-title":"Cancer-derived exosomes as a delivery platform of CRISPR\/Cas9 confer cancer cell tropism-dependent targeting","volume":"266","author":"Kim","year":"2017","journal-title":"J. Control. Release"},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.2147\/IJN.S231214","article-title":"Exosome-delivered c-Met siRNA could reverse chemoresistance to cisplatin in gastric cancer","volume":"15","author":"Zhang","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"ref_308","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-019-0981-7","article-title":"Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer","volume":"18","author":"Liu","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-020-2250-5","article-title":"Exosome-transmitted miR-567 reverses trastuzumab resistance by inhibiting ATG5 in breast cancer","volume":"11","author":"Han","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"6756","DOI":"10.18632\/aging.103036","article-title":"Exosomal miR-200c suppresses chemoresistance of docetaxel in tongue squamous cell carcinoma by suppressing TUBB3 and PPP2R1B","volume":"12","author":"Cui","year":"2020","journal-title":"Aging"},{"key":"ref_311","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-03705-y","article-title":"Progress and challenges towards targeted delivery of cancer therapeutics","volume":"9","author":"Rosenblum","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_312","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/nbt1006-1211","article-title":"The emerging nanomedicine landscape","volume":"24","author":"Wagner","year":"2006","journal-title":"Nat. Biotechnol."},{"key":"ref_313","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3389\/fphar.2015.00286","article-title":"Advances and challenges of liposome assisted drug delivery","volume":"6","author":"Sercombe","year":"2015","journal-title":"Front. Pharmacol."},{"key":"ref_314","doi-asserted-by":"crossref","first-page":"790","DOI":"10.3389\/fphar.2018.00790","article-title":"Current trends and challenges in the clinical translation of nanoparticulate nanomedicines: Pathways for translational development and commercialization","volume":"9","author":"Hua","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_315","doi-asserted-by":"crossref","first-page":"e1416","DOI":"10.1002\/wnan.1416","article-title":"Investigational nanomedicines in 2016: A review of nanotherapeutics currently undergoing clinical trials","volume":"9","author":"Caster","year":"2017","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"ref_316","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: From concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_317","doi-asserted-by":"crossref","first-page":"11147","DOI":"10.1021\/acs.chemrev.5b00116","article-title":"Clinical translation of nanomedicine","volume":"115","author":"Min","year":"2015","journal-title":"Chem. Rev."},{"key":"ref_318","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1177\/1060028018764923","article-title":"Daunorubicin and cytarabine liposome in newly diagnosed therapy-related Acute Myeloid Leukemia (AML) or AML with myelodysplasia-related changes","volume":"52","author":"Kim","year":"2018","journal-title":"Ann. Pharmacother."},{"key":"ref_319","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/13577140500287024","article-title":"Phase II clinical trial with pegylated liposomal doxorubicin (Caelyx\u00ae\/Doxil\u00ae) and quality of life evaluation (EORTC QLQ-C30) in adult patients with advanced soft tissue sarcomas: A study of the Spanish Group for Research in Sarcomas (GEIS)","volume":"9","author":"Poveda","year":"2005","journal-title":"Sarcoma"},{"key":"ref_320","unstructured":"Giri, B.P., Gregg, K., Singh, P., Dagli, D.J., and Giri, A. (2014). Hypoxia-Targeted Polymeric Micelles for Cancer Therapy and Imaging. (13,804,007), U.S. Patent."},{"key":"ref_321","doi-asserted-by":"crossref","first-page":"e10143","DOI":"10.1002\/btm2.10143","article-title":"Nanoparticles in the clinic: An update","volume":"4","author":"Anselmo","year":"2019","journal-title":"Bioeng. Transl. Med."},{"key":"ref_322","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/0277-5379(89)90350-7","article-title":"Systemic administration of doxorubicin-containing liposomes in cancer patients: A phase I study","volume":"25","author":"Gabizon","year":"1989","journal-title":"Eur. J. Cancer Clin. Oncol."},{"key":"ref_323","first-page":"2592","article-title":"Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007) Phase I study of patients with squamous cell carcinoma of the head and neck and anal canal: Preliminary evidence of clinical activity","volume":"92","author":"Damascelli","year":"2001","journal-title":"Cancer Interdiscip. Int. J. Am. Cancer Soc."},{"key":"ref_324","doi-asserted-by":"crossref","first-page":"6139","DOI":"10.1158\/1078-0432.CCR-10-0978","article-title":"Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine","volume":"16","author":"Libutti","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_325","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/sj.bjc.6603855","article-title":"A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation","volume":"97","author":"Hamaguchi","year":"2007","journal-title":"Br. J. Cancer"},{"key":"ref_326","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.1002\/cncr.24632","article-title":"Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia","volume":"115","author":"Thomas","year":"2009","journal-title":"Cancer"},{"key":"ref_327","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/annonc\/mdn661","article-title":"Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel)(Abraxane\u00ae) in combination with gemcitabine in patients with metastatic breast cancer (N0531)","volume":"20","author":"Roy","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_328","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1158\/1078-0432.CCR-10-0387","article-title":"Phase I study of NK012, a novel SN-38\u2013incorporating micellar nanoparticle, in adult patients with solid tumors","volume":"16","author":"Hamaguchi","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_329","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1470-2045(12)70476-X","article-title":"Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: A phase 1 dose-escalation study","volume":"13","author":"Mamot","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_330","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.clml.2013.03.015","article-title":"Phase I\/II trial of nanomolecular liposomal annamycin in adult patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"13","author":"Wetzler","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_331","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1002\/jcph.155","article-title":"Pharmacokinetics and pharmacodynamics of vincristine sulfate liposome injection (VSLI) in adults with acute lymphoblastic leukemia","volume":"53","author":"Silverman","year":"2013","journal-title":"J. Clin. Pharmacol."},{"key":"ref_332","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1093\/annonc\/mdt002","article-title":"A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma","volume":"24","author":"Roy","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_333","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1007\/s10637-012-9921-8","article-title":"First-in-human phase 1\/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies","volume":"31","author":"Weiss","year":"2013","journal-title":"Investig. New Drugs"},{"key":"ref_334","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/mt.2013.32","article-title":"Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors","volume":"21","author":"Senzer","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_335","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1158\/1078-0432.CCR-15-2548","article-title":"Phase I study of PSMA-targeted docetaxel-containing nanoparticle BIND-014 in patients with advanced solid tumors","volume":"22","author":"Mita","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_336","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12032-017-1009-z","article-title":"Phase II study of paclitaxel associated with lipid core nanoparticles (LDE) as third-line treatment of patients with epithelial ovarian carcinoma","volume":"34","author":"Graziani","year":"2017","journal-title":"Med. Oncol."},{"key":"ref_337","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/1078-0432.CCR-17-1114","article-title":"Phase Ib\/II Trial of NC-6004 (Nanoparticle Cisplatin) plus gemcitabine in patients with advanced solid tumors","volume":"24","author":"Subbiah","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_338","unstructured":"Conner, J.B., Bawa, R., Nicholas, J.M., and Weinstein, V.J. (2014). Copaxone in the era of biosimilars and nanosimilars. Handbook of Clinical Nanomedicine-from Bench too Bedside, Pan Stanford Publishing Pte Ltd."},{"key":"ref_339","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s10637-016-0422-z","article-title":"A first-in-human Phase 1 study of epirubicin-conjugated polymer micelles (K-912\/NC-6300) in patients with advanced or recurrent solid tumors","volume":"35","author":"Mukai","year":"2017","journal-title":"Investig. New Drugs"},{"key":"ref_340","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s10637-016-0407-y","article-title":"Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors","volume":"35","author":"Beg","year":"2017","journal-title":"Investig. New Drugs"},{"key":"ref_341","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1007\/s13277-012-0496-y","article-title":"A clinical study on regional lymphatic chemotherapy using an activated carbon nanoparticle\u2013epirubicin in patients with breast cancer","volume":"33","author":"Yang","year":"2012","journal-title":"Tumor Biol."},{"key":"ref_342","doi-asserted-by":"crossref","first-page":"e34833","DOI":"10.1371\/journal.pone.0034833","article-title":"Phase I clinical trial of systemically administered TUSC2 (FUS1)-nanoparticles mediating functional gene transfer in humans","volume":"7","author":"Lu","year":"2012","journal-title":"PLoS ONE"},{"key":"ref_343","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/mt.2009.126","article-title":"Phase I\/II and phase II studies of targeted gene delivery in vivo: Intravenous Rexin-G for chemotherapy-resistant sarcoma and osteosarcoma","volume":"17","author":"Chawla","year":"2009","journal-title":"Mol. Ther."},{"key":"ref_344","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1080\/1061186X.2019.1566339","article-title":"Pharmacokinetic analysis reveals limitations and opportunities for nanomedicine targeting of endothelial and extravascular compartments of tumours","volume":"27","author":"Benchimol","year":"2019","journal-title":"J. Drug Target."},{"key":"ref_345","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/0008-5472.CAN-12-4561","article-title":"Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology","volume":"73","author":"Prabhakar","year":"2013","journal-title":"Cancer Res."},{"key":"ref_346","first-page":"114","article-title":"Lost in translation: Animal models and clinical trials in cancer treatment","volume":"6","author":"Mak","year":"2014","journal-title":"Am. J. Transl. Res."},{"key":"ref_347","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.addr.2012.10.002","article-title":"The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo","volume":"65","author":"Maeda","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_348","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41524-020-00366-8","article-title":"In silico modelling of cancer nanomedicine, across scales and transport barriers","volume":"6","author":"Stillman","year":"2020","journal-title":"npj Comput. Mater."},{"key":"ref_349","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/j.addr.2013.05.005","article-title":"Molecular modeling in structural nano-toxicology: Interactions of nano-particles with nano-machinery of cells","volume":"65","author":"Yanamala","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_350","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.xphs.2018.10.037","article-title":"Physiologically Based Pharmacokinetic Modeling of Nanoparticles","volume":"108","author":"Yuan","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"ref_351","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3892\/or.2017.5718","article-title":"Cancer drug delivery in the nano era: An overview and perspectives","volume":"38","author":"Li","year":"2017","journal-title":"Oncol. Rep."},{"key":"ref_352","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1021\/acsnano.5b07522","article-title":"High-density lipoproteins: Nature\u2019s multifunctional nanoparticles","volume":"10","author":"Kuai","year":"2016","journal-title":"ACS Nano"},{"key":"ref_353","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3389\/fphar.2018.00735","article-title":"The advances and challenges in utilizing exosomes for delivering cancer therapeutics","volume":"9","author":"Yang","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_354","doi-asserted-by":"crossref","unstructured":"Adhipandito, C.F., Cheung, S.-H., Lin, Y.-H., and Wu, S.-H. (2021). Atypical Renal Clearance of Nanoparticles Larger Than the Kidney Filtration Threshold. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222011182"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/4\/866\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:54:41Z","timestamp":1760136881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/4\/866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,15]]},"references-count":354,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["pharmaceutics14040866"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics14040866","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,15]]}}}